ProMIS Neurosciences Inc PMN

Phase 1b

[Blueknowser1]

Can't wait to hear some of the positive results. Love the name: 

Mr. Warma added “the trial name, PRECISE-AD, was chosen to reflect our focus on Personalized, Robust, and Effective Clinical Intervention with Specificity and Excellence in addressing Alzheimer’s Disease. 

[BottomBroker]

"We are excited about the opportunity to deliver real innovation to patients and look forward to sharing updates as we progress, with certain interim data anticipated in the first half of 2026". So does this mean we won't see any biomarker results in six months as previously discussed?

[G1945V]

In October, they reported the following on the Phase 1A: "PMN310 was generally well-tolerated in all five single-ascending dose cohorts (2.5, 5, 10, 20 and 40 mg/kg) of the Phase 1a clinical trial and, importantly, crossed the blood brain barrier in healthy volunteers in a dose-dependent manner with pharmacokinetics suggesting that monthly dosing may provide levels of PMN310 adequate for

[Blueknowser1]

CEO Warma mentions while speaking at the HealthCONx Conference, that there'd potentially be updates sooner, but without listening to that webcast again, I'm not sure.

[bball67]

Promis has committed to releasing biomarker results after six months of treatment of PMN310 by press release and a SEC filing. There are about 8 or 9 biomarkers. After this, warrant holders from the last financing will have 30 days to exercise warrants. This is public information. I believe they could be nearly out of cash in maybe September, so there will be urgency to release these results to

[Gbathat]

Seems great.  Based on their past behavior, I'd suspect a partnership approach.  Unless they are just exhausted and ready to cash out themselves.  But I feel like the technical dev team has always been interested more in the technical and humanitarian outcome than the financial outcome, which has probably impacted previous decisions when sharks were initially circling. 

[Blueknowser1]

All good information- thanks!